Document is current
Any future updates will be listed below
-
Authors
Dinah, Christiana https://orcid.org/0000-0002-0815-4771
Enoch, Jamie https://orcid.org/0000-0002-4614-6676
Ghulakhszian, Arevik
Taylor, Deanna J. https://orcid.org/0000-0001-8261-5225
Crabb, David P.
- License Information
-
More Information
Article History
Received: 12 April 2021
Revised: 21 April 2021
Accepted: 28 April 2021
First Online: 18 May 2021
Compliance with ethical standards
:
: CD has served on advisory boards for Novartis, Allergan and Apellis. JE, AG and DJT have no interests to declare. DPC reports grants from Roche, grants and personal fees from Santen, grants and personal fees from Apellis, grants from Allergan, personal fees from Thea, personal fees from Bayer and personal fees from Centervue, outside the submitted work. DPC receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant 116076 (Macustar). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA). The communication reflects the author’s view and that neither IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained therein.
